HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E1991 BBI-355 BBI-355 is an oral, potent, and selective small molecule inhibitor of CHK1 with an IC50 of 0.3 nM. It demonstrates significant anti-tumor activity as a single agent and in combination with targeted therapies in multiple ecDNA+ oncogene amplified tumor models. Mar 14 2025
E6040 Imiquimod maleate Imiquimod maleate (R 837 maleate) is a small-molecule salt derivative of maleic acid, isolated from the Imiquimod free base and is an immune response modifier, a potent and selective agonist of toll like receptor 7 (TLR7), an antagonist of adenosine A₂A receptor with a Ki of 2.16 μM, and an inhibitor of adenylyl cyclase activity, inducing antiviral proteins like cystatin A. It exhibits strong antitumoral and antiviral efficacy, making it effective for conditions such as COVID 19, HPV warts, molluscum contagiosum, actinic keratosis, basal and squamous cell carcinoma, Bowen's disease, and vulvar intraepithelial neoplasia. Mar 14 2025
E5848 ERAS-0015 ERAS-0015(JYP0015) is a tricomplex inhibitor of panRAS(ON) targeting of active RAS, it binds to Cyclophilin A (CYPA) to form a high-affinity complex that sterically occludes RAS–effector interactions. It exhibits potential for research in RAS-mutant solid tumors. Mar 11 2025
E5887 Osavampator Osavampator (TAK-653, NBI-1065845) is a positive allosteric modulator (PAM) of AMPA receptors. It enhances glutamate-induced calcium influx in CHO cells expressing human AMPA receptors with an EC50 of 3.3 µM and potentiates AMPA receptor-mediated currents in rat primary hippocampal neurons with an EC50 of 4.4 µM. Mar 10 2025
E1938 HRX215 HRX215 (Darizmetinib) is a first-in-class, highly potent, selective, and orally active inhibitor of MKK4 with an IC50 of 0.02 µM. It enhances liver regeneration, prevents liver failure following extensive hepatectomy in pigs, and has potential to prevent liver failure after major oncological liver resections or transplantation of small liver grafts in humans. Mar 10 2025
A4002 Cadonilimab (Anti-PD-1 & CTLA-4) Cadonilimab is a humanized tetravalent bispecific IgG1 antibody targeting human PD-1 and CTLA-4 with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat recurrent or metastatic cervical cancer. MW : 198.64 KD. Mar 09 2025
A4003 Pm8002 (Anti-PD-L1 & VEGF) Pm8002 is a bispecific antibody targeting both PD-L1 and VEGF-A, with potential immune checkpoint inhibition, anti-angiogenic, and antineoplastic activities. It demonstrates promising antitumor effects in patients with previously treated platinum-resistant recurrent ovarian cancer (PROC) or cervical cancer, as well as in those with advanced solid tumors. MW : 172.48 KD. Mar 09 2025
A4004 Lutikizumab (Anti-IL-1α & IL-1β) Lutikizumab is a humanized dual-variable domain (DVD) immunoglobulin G1 kappa (IgG1κ) that targets the inflammatory cytokines human interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β), exhibiting anti-inflammatory properties. It shows potential for treating knee osteoarthritis in patients with synovitis. MW: 196.82 KD. Mar 09 2025
A4006 Sonelokimab (Anti-IL-17 & IL-17F & Serum Albumin) Sonelokimab is a humanized trivalent nanobody consisting of monovalent camelid-derived nanobodies that target human interleukin (IL)-17A, IL-17F, and human serum albumin. It exhibits clinical efficacy and dose-dependent modulation of psoriasis-associated genes in patients with plaque-type psoriasis. MW: 40.93 KD. Mar 09 2025
A4007 Duligotuzumab (Anti-EGFR & HER3) Duligotuzumab is a dual-action humanized IgG1 antibody that blocks ligand binding to the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). By inhibiting these interactions, it disrupts signalling from all ligand-dependent HER dimers and induces antibody-dependent cell-mediated cytotoxicity. It exhibits enhanced efficacy in EGFR inhibitor-resistant SCCHN and NSCLC models, with potential benefits for tumors with high neuregulin 1 (NRG1) expression. MW: 144.78 KD. Mar 09 2025
A4008 Epcoritamab (Anti-CD20 & CD3) Epcoritamab is a bispecific IgG1 antibody that targets CD3 and CD20, exhibiting strong T-cell-mediated cytotoxic activity against CD20+ malignant B cells. It is used in the treatment of adults in relapsed or refractory (R/R) large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma after ≥2 lines of systemic treatment. MW: 145.26 KD. Mar 09 2025
A4009 Rilvegostomig (Anti-PD-1 & TIGIT) Rilvegostomig is a bispecific humanized IgG1 antibody that targets the immunoregulatory receptor programmed cell death protein 1 (PD-1) and the co-inhibitory immune checkpoint molecule T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT). It enhances T-cell activation and promotes a robust anti-tumor immune response, particularly in cancers like non-small cell lung cancer (NSCLC). MW: 146.06. Mar 09 2025
A4010 Elranatamab-Bcmm (Anti-BCMA & CD3) Elranatamab-bcmm is a bispecific T-cell engager (BiTE) monoclonal antibody that targets CD3 and B-cell maturation antigen (BCMA), promoting the recruitment and activation of T cells to effectively eliminate malignant myeloma cells. It is FDA-approved for the treatment of adults with relapsed or refractory multiple myeloma. MW: 145.44 KD. Mar 09 2025
A4011 Hb0025 (Anti-PD-L1 & VEGF) Hb0025 is a bispecific antibody that targets PD-L1 and vascular endothelial growth factor (VEGF), with EC50 values of 0.67 nM and 0.48 nM, respectively. It exerts anti-tumor effects by inhibiting VEGF activity and promoting T-cell infiltration into tumors, thereby transforming the immunosuppressive tumor microenvironment into an immune-activated state. MW: 170.8 KD. Mar 09 2025
A4012 Tqb2858 (Anti-PD-L1 & TGF-β) Tqb2858 is a bifunctional fusion protein consisting of a monoclonal antibody targeting programmed death ligand 1 (PD-L1) fused with the extracellular domain of the transforming growth factor beta (TGF-β) receptor. It simultaneously neutralizes TGF-β on tumor cells and inhibits PD-L1 activity, exhibiting potential antineoplastic and immune checkpoint-modulating effects. MW: 178.22 KD. Mar 09 2025
A4013 Istiratumab (Anti-HER3 & IGF-1R) Istiratumab is a fully human tetravalent bispecific antibody that binds to and co-inhibits IGF-1R and the epidermal growth factor family of receptor tyrosine kinases B3 (ErbB3), with potential anti-tumor activity. MW: 199.64 KD. Mar 09 2025
A4014 Hx009 (Anti-CD47 & PD-1) Hx009 is a humanized bispecific antibody fusion protein targeting the immunoregulatory checkpoint receptors PD-1 and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing, and antineoplastic activities. It exhibits anti-tumor effects in patients with advanced malignancies. MW: 173.16 KD. Mar 09 2025
A4015 Glofitamab (Anti-CD20 & CD3) Glofitamab is a T-cell–engaging bispecific antibody that targets CD3 and CD20, demonstrating significant antitumor activity and durable responses in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). It works by binding to CD20 on B cells and CD3 on T cells, promoting T-cell-mediated lysis of malignant B cells. MW: 170.28 KD. Mar 09 2025
A4016 TNB-383B (Anti-BCMA & BCMA & CD3) TNB-383B is a fully human bispecific T-cell engager (T-BsAb) monoclonal antibody that targets B-cell maturation antigen (BCMA) and CD3, demonstrating potent anti-tumor activity in patients with relapsed or refractory multiple myeloma (MM). It works by binding to BCMA on malignant plasma cells and CD3 on T cells, facilitating T-cell-mediated lysis of myeloma cells while minimizing cytokine release. MW: 123.79 KD. Mar 09 2025
A4017 Mas825 (Anti-IL-18 & IL-1β) Mas825 is a bispecific antibody targeting both IL-1β and IL-18, effectively modulating the inflammasome cascade in inflammatory diseases. It shows potential for treating patients with COVID-19 and systemic juvenile idiopathic arthritis (sJIA) complicated by macrophage activation syndrome (MAS) and interstitial lung disease (ILD) by reducing pro-inflammatory cytokines and neutrophil counts, thereby improving clinical outcomes. MW: 144.15 kDa. Mar 09 2025